Market Research Life Sciences Market Research Pharmaceuticals Market Research Therapeutic Area Market Research Renal Market Research

Chronic Kidney Disease: Seven-Market Drug Forecast and Market Analysis

Best Price Guarantee Length Publisher Published Date SKU
from $10,995 95 Pages GlobalData June, 2024 GBDT18974370
Best Price Guarantee
Price from $10,995
Length 95 Pages
Publisher GlobalData
Published Date June, 2024
SKU GBDT18974370

Chronic Kidney Disease: Seven-Market Drug Forecast and Market Analysis


Summary

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Chronic Kidney Disease (CKD) market through 2033.

GlobalData estimates the sales of CKD therapeutics to be approximately $2.2 billion across the 7MM in 2023. By 2033, GlobalData expects the CKD market to grow at a strong compound annual growth rate (CAGR) of 19.6%, reaching sales of $13.5 billion by the end of the forecast period.

The major drivers of CKD market growth over the forecast period are the:
  • Anticipated expanded indication for glucagon-like peptide 1 (GLP-1) receptor agonist, Novo Nordisk’s Ozempic (semaglutide)
  • Launch of eight oral pipeline agents and six injectable pipeline agents
  • Increase in the global prevalence of CKD.
The major barriers that will restrict the growth of the CKD market during the forecast period are the:
  • High price of recently developed CKD therapies
  • General reluctance of nephrologists and other physicians to adopt and prescribe new CKD therapies.
  • Widespread use of generic CKD drugs, making it difficult for high-priced branded therapies to penetrate the market.
Key Highlights
  • GlobalData estimates the sales of CKD therapeutics to be approximately $2.2 billion across the 7MM in 2023. By 2033, GlobalData expects the CKD market to grow at a strong compound annual growth rate (CAGR) of 19.6%, reaching sales of $13.5 billion by the end of the forecast period.
  • The major drivers of CKD market growth over the forecast period are the:
  • Anticipated expanded indication for glucagon-like peptide 1 (GLP-1) receptor agonist, Novo Nordisk’s Ozempic (semaglutide)
  • Launch of eight oral pipeline agents and six injectable pipeline agents
  • Increase in the global prevalence of CKD.
Scope
  • Overview of CKD, including epidemiology, symptoms, diagnosis, and disease management.
  • Annualized CKD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the CKD therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for CKD treatment. The most promising candidates in late-stage development are profiled.
  • Analysis of the current and future market competition in the global CKD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the 7MM CKD therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM CKD therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Please note:this is delivered as a Zip file.


1 Chronic Kidney Disease: Executive Summary
1.1 The CKD market will exhibit strong growth between 2023 and 2033.
1.2 Label expansions of cardiovascular drugs will fuel market growth.
1.3 Unmet needs remain in the CKD market despite the availability of well-established therapies.
1.4 Oral agents will dominate the CKD market.
1.5 What do physicians think?
2 Introduction
2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports
3 Disease Overview
3.1 Etiology and pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification or staging systems
4 Epidemiology
4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 7MM forecast methodology.
4.4.1 Sources
4.4.2 Forecast assumptions and methods.
4.4.3 Total prevalent cases of CKD
4.4.4 Total prevalent cases of CKD by stage
4.4.5 Diagnosed prevalent cases of CKD.
4.4.6 Diagnosed prevalent cases of CKD by stage.
4.4.7 Diagnosed prevalent cases of CKD based on dialysis dependence.
4.5 Epidemiological forecast for CKD (2023-33)
4.5.1 Total prevalent cases of CKD
4.5.2 Total prevalent cases of CKD by stage
4.5.3 Diagnosed prevalent cases of CKD.
4.5.4 Age-specific diagnosed prevalent cases of CKD
4.5.5 Sex-specific diagnosed prevalent cases of CKD
4.5.6 Diagnosed prevalent cases of CKD by stage.
4.5.7 Diagnosed prevalent cases of CKD by dialysis dependence.
4.6 Discussion
4.6.1 Epidemiological forecast insight
4.6.2 COVID-19 impact.
4.6.3 Limitations of the analysis
4.6.4 Strengths of the analysis
5 Disease Management
5.1 Diagnosis and treatment overview
5.2 KOL insights on disease management
6 Current Treatment Options
6.1 Overview
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Lack of efficacious drugs
7.3 Drug cost and market access
7.4 Lack of education and awareness of new products
7.5 Compliance and optimal management of CKD treatments
8 R&D Strategies
8.1 Overview
8.1.1 Label expansion for therapies approved for other indications.
8.1.2 Mergers and acquisitions to expand the product pipeline.
8.2 Clinical trials design
8.2.1 Clinical endpoints for CKD
8.2.2 Inclusion and exclusion criteria
9 Pipeline Assessment
9.1 Overview
9.2 Promising drugs in clinical development
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive assessment
11 Current and Future Players
11.1 Overview
11.2 Deal-making trends
12 Market Outlook
12.1 Seven major markets
12.1.1 Forecast
12.1.2 Drivers and barriers - global Issues
12.2 US
12.2.1 Forecast
12.2.2 Key events
12.2.3 Drivers and barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key events
12.3.3 Drivers and barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key events
12.4.3 Drivers and barriers
13 Appendix
13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.3.1 Forecasting methodology
13.4 Primary research - KOLs interviewed for this report.
13.4.1 KOLs
13.5 Primary research - prescriber survey
13.6 About the authors
13.6.1 Analyst
13.6.2 Therapy Area Director
13.6.3 Epidemiologist
13.6.4 Vice President of Disease Intelligence and Epidemiology
13.6.5 Global Head of Pharma Research, Analysis, and Competitive Intelligence
Contact Us
List of Tables
Table 1: CKD: key metrics in the 7MM
Table 2: Stages of CKD
Table 3: KDIGO classification of CKD
Table 4: Risk factors and comorbid conditions associated with CKD
Table 5: Common diagnostic tests for CKD
Table 6: Treatment guidelines for CKD
Table 7: Top 10 deals by value, 2022-24
Table 8: CKD market - global drivers and barriers, 2023-33
Table 9: Key events impacting sales for CKD in the US, 2023-33
Table 10: CKD Market - Drivers and Barriers in the US, 2023-33
Table 11: Key events impacting sales for CKD in the 5EU, 2023-33
Table 12: CKD Market - Drivers and Barriers in the 5EU, 2023-33
Table 13: Key events impacting sales for CKD in Japan, 2023-33
Table 14: CKD Market - Drivers and Barriers in Japan, 2023-33
Table 15: High-prescribing physicians (non-KOLs) surveyed, by country
List of Figures
Figure 1: Global sales forecast by country for CKD in 2023 and 2033
Figure 2: Analysis of the company portfolio gap in CKD during the forecast period
Figure 3: Competitive assessment of the oral late-stage pipeline agents that GlobalData expects to be licensed for the treatment of CKD during the forecast period
Figure 4: Competitive assessment of the injectable late-stage pipeline agents that GlobalData expects to be licensed for the treatment of CKD during the forecast period
Figure 5: The etiology of CKD
Figure 6: The pathophysiology of CKD
Figure 7: 7MM, diagnosed prevalence of CKD (%), men, ages ≥18 years, 2023
Figure 8: 7MM, total prevalence of CKD (%), women, ages ≥18 years, 2023
Figure 9: 7MM, sources used and not used to forecast the total prevalent cases of CKD
Figure 10: 7MM, sources used to forecast the total prevalent cases of CKD by stage
Figure 11: 7MM, sources used to forecast the diagnosed prevalent cases of CKD
Figure 12: 7MM, sources used to forecast the diagnosed prevalent cases of CKD by stage
Figure 13: 7MM, sources used to forecast the diagnosed prevalent cases of CKD by dialysis dependence
Figure 14: 7MM, total prevalent cases of CKD, N, both sexes, ages ≥18 years, 2023
Figure 15: 7MM, total prevalent cases of CKD by stage, N, both sexes, ages ≥18 years, 2023
Figure 16: 7MM, diagnosed prevalent cases of CKD, N, both sexes, ages ≥18 years, 2023
Figure 17: 7MM, diagnosed prevalent cases of CKD by age group, N, both sexes, 2023
Figure 18: 7MM, diagnosed prevalent cases of CKD by sex, N, ages ≥18 years, 2023
Figure 19: 7MM, diagnosed prevalent cases of CKD by stage, N, both sexes, ages ≥18 years, 2023
Figure 20: 7MM, diagnosed prevalent cases of CKD by dialysis dependence, N, both sexes, ages ≥18 years, 2023
Figure 21: 7MM, diagnosed prevalent cases of CKD based on dialysis-dependence subtype, N, both sexes, ages ≥18 years, 2023
Figure 22: Unmet needs and opportunities in CKD
Figure 23: Overview of the development pipeline in CKD
Figure 24: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for the treatment of CKD in the 7MM during the forecast period
Figure 25: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of CKD during the forecast period
Figure 26: Competitive assessment of the oral pipeline drugs benchmarked against the standard of care
Figure 27: Competitive assessment of the injectable pipeline drugs benchmarked against the standard of care
Figure 28: Analysis of the company portfolio gap in CKD during the forecast period
Figure 29: 7MM sales forecast by country for CKD in 2023 and 2033
Figure 30: Sales forecast by class for CKD in the US in 2023 and 2033
Figure 31: Sales forecast by class for CKD in the 5EU in 2023 and 2033
Figure 32: Sales forecast by class for CKD in Japan in 2023 and 2033

$10,995
$21,990
$32,985

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings